

SIPR

Atty. Dkt. No. 029488-0113

UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Philippe ROUANET et al.

Title: PREVENTION AND TREATMENT OF BREAST
CANCER WITH 4-HYDROXY TAMOXIFEN

Appl. No.: 10/734,638

Filing Date: 12/15/2003

Examiner: Unassigned

Art Unit: 1615

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits, and within three (3) months of the mailing date of the foreign search report.

RELEVANCE OF EACH DOCUMENT

The relevance of the foreign-language document is described in the present specification. An English translation of the foreign-language document is not readily available. However, the absence of such translation does not relieve the PTO from its duty to consider the submitted foreign language document (37 CFR §1.98 and MPEP §609).

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.


Respectfully submitted,

Date 6 January 2005

By S. A. Bent

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5404
Facsimile: (202) 672-5399

Stephen A. Bent
Attorney for Applicant
Registration No. 29,768



MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: January 6, 2005

(use as many sheets as necessary)

Sheet

1

of 3

Complete if Known

Application Number	10/734,638
Filing Date	12/15/2003
First Named Inventor	Philippe ROUANET et al.
Group Art Unit	Unassigned
Examiner Name	1615

Attorney Docket Number 029488-0113

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
B1	5,904,930			Hexel AG	5/18/1999	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
B2		J. BARRAT et al., "Effet <i>in vivo</i> de l'administration locale de progestérone sur l'activité mitotique des galactophores humains", <i>J. Gynecol. Obstet. Biol. Reprod.</i> 19: 269-274 1990.	
B3		Bronaugh & Maibach, "Percutaneous Absorption Drugs-Cosmetics-Mechanisms-Methodology", Marcel Dekker Inc., New York, 1999.	
B4		Philip CARTHEW et al., "Cumulative exposure to tamoxifen: DNA adducts and liver cancer in the rat", <i>Arch Toxicol</i> (2001) 75: 375-380.	
B5		Gerard CHETRITE et al., "Effect of Promegestone, Tamoxifen, 4-Hydroxytamoxifen and ICI 164,384 on the Oestrone Sulphatase Activity of Human Breast Cancer Cells", <i>Anticancer Research</i> 13: 931-934 (1993).	
B6		Eric C. DIETZE et al., "Tamoxifen but Not 4-Hydroxytamoxifen Initiates Apoptosis in p53(-) Normal Human Mammary Epithelial Cells by Inducing Mitochondrial Depolarization", <i>The Journal of Biological Chemistry</i> Vol. 276, No. 7, Issue of February 16, 2001, pp. 5384-5394.	
B7		I.S. FENTIMAN et al., "Dosage and duration of tamoxifen treatment for mastalgia: a controlled trial", <i>BR. J. SURG.</i> September 1988, Vol. 75, No. 9, pp. 845-846.	
B8		I.S. FENTIMAN et al., "Studies of tamoxifen in women with mastalgia*", <i>The British Journal of Clinical Practice</i> , Supplement 68, Vol. 43, No. 11, November 1989, pp. 34-36.	
B9		N. GIAMBIAGI et al., "IMMUNOLOGICAL DIFFERENCES BETWEEN THE ESTRADIOL-, TAMOXIFEN- AND 4-HYDROXY-TAMOXIFEN-ESTROGEN RECEPTOR COMPLEXES DETECTED BY TWO MONOCLONAL ANTIBODIES", <i>J. Steroid Biochem.</i> Vol. 30, No. 1-6, pp. 213-217, 1988.	

Examiner Signature


Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute Form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Date Submitted: January 6, 2005

(use as many sheets as necessary)

Sheet

2

of

3

Complete if Known

Application Number	10/734,638
Filing Date	12/15/2003
First Named Inventor	Philippe ROUANET et al.
Group Art Unit	Unassigned
Examiner Name	1615

Attorney Docket Number 029488-0113

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	B10	V. Craig JORDAN et al., "Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance", Breast Cancer Research and Treatment, 2, pp. 123-138.	
	B11	George G.J.M. KUIPER et al., "Comparison of the Ligand Binding Specificity and Transcript Tissue Distribution of Estrogen Receptors α and β ", Endocrinology, Vol. 138, No. 3, 1997, pp. 863-870.	
	B12	Frédérique KUTTENN et al., "MÉDECINE ET THÉRAPEUTIQUE", C.R. Acad. Sc. Paris, , Série III, No. 12, 1985, 300:457-461.	
	B13	Catherine MALET et al., "Tamoxifen and Hydroxytamoxifen Isomers versus Estradiol Effects on Normal Human Breast Cells in Culture", Cancer Research, Vol. 48, No. 24, December 15, 1988, pp. 7193-7199.	
	B14	Pierre MAUVAIS-JARVIS et al., "trans-4-Hydroxytamoxifen Concentration and Metabolism after Local Percutaneous Administration to Human Breast", Cancer Research, Vol. 46, March 1986, pp. 1521-1525.	
	B15	David W. ROBERTSON et al., "Synthesis of the E and Z Isomers of the Antiestrogen Tamoxifen and Its Metabolite, Hydroxytamoxifen, in Tritium-Labeled Form", J. Org. Chem., 1982, Vol. 47, No. 12, pp. 2387-2393.	
	B16	David W. ROBERTSON et al., "TAMOXIFEN ANTIESTROGENS, A COMPARISON OF THE ACTIVITY, PHARMACOKINETICS, AND METABOLIC ACTIVATION OF THE C/S AND TRANS ISOMERS OF TAMOXIFEN" Journal of Steroid Biochemistry, Vol. 16, pp. 1-13, (1982).	
	B17	Fabrice SAUVEZ et al., "Cutaneously applied 4-hydroxytamoxifen is not carcinogenic in female rats", Carcinogenesis Vol. 20, No. 5, pp. 843-850 1999.	
	B18	Ashini L. WIJAYARATNE et al., "Comparative Analyses of Mechanistic Differences Among Antiestrogens", Endocrinology, Vol. 140, No. 2, pp. 5828-5840.	
	B19	"First results from the International Breast Cancer Intervention Study (IBIS-I): a randomized prevention trial", The Lancet, Vol. 360, September 14, 2002, pp. 817-824.	
	B20	Carsten SCHLÜTER et al. "The Cell Proliferation-associated Antigen of Antibody Ki-67: A Very Large, Ubiquitous Nuclear Protein with Numerous Repeated Elements, Representing a New Kind of Cell Cycle-maintaining Proteins", The Journal of Cell Biology, Volume 123, 1993, pp. 513-522.	
	B21	Debra J. BEVITT et al., "New Monoclonal Antibodies to Oestrogen and Progesterone Receptors Effective for Paraffin Section Immunohistochemistry", Journal of Pathology, Vol. 183, (1997) pp. 228-232.	
	B22	Lawrence H. BLOCK Ph.D., Epidermal and Transdermal Drug Delivery", Medicated Topicals, Chapter 44, pp. 836-857.	
	B23	Corinne CHARLIER et al., "Tamoxifen and Its Active Metabolite Inhibit Growth of Estrogen Receptor-Negative MDA-MB-435 Cells", Biochemical Pharmacology, Vol. 49, No. 3, pp. 351-358, 1995.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/734,638
Date Submitted: January 6, 2005 (use as many sheets as necessary)				Filing Date	12/15/2003
				First Named Inventor	Philippe ROUANET et al.
				Group Art Unit	Unassigned
				Examiner Name	1615
Sheet	3	of	3	Attorney Docket Number	029488-0113

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	1 ²
	B24	Ian S. FENTIMAN, "Tamoxifen and Mastalgia An Emerging Indication", Drugs 32" 477-480 (1986), pp. 477-480.	
	B25	Johannes GERDES et al., "CELL CYCLE ANALYSIS OF A CELL PROLIFERATION-ASSOCIATED HUMAN NUCLEAR ANTIGEN DEFINED BY THE MONOCLONAL ANTIBODY Ki-67 ¹ ", The Journal of Immunology, Vol. 133, No. 4, October 1984, pp. 1710-1715.	
	B26	J. GIRAUT et al., "Quantitative Measurement of 4-Hydroxy Tamoxifen in Human Plasma and Mammary Tumours by Combined Gas Chromatography/Negative Chemical Ionization Mass Spectrometry", Biological Mass Spectrometry, Vol. 22, (1993) pp. 395-402.	
	B27	Trisha GURA, "Cancer Models: Systems for Identifying New Drugs Are Often Faulty", Science, Vol. 278, November 7, 1997, pp. 1041-1042.	
	B28	Stanley G. KORENMAN et al., "ESTRADIOL RADIOIMMUNOASSAY WITHOUT CHROMATOGRAPHY: PROCEDURE, VALIDATION AND NORMAL VALUES", J. Clin. Endocrinol. Metab. 38:718-720 (1974).	
	B29	Catherine MALET et al., "Effect of 4-hydroxytamoxifen isomers on growth and ultrastructural aspects of noram human breast epithelial (HBE) cells in culture", Journal of Steroid Biochemistry & Molecular Biology 82, (2002) pp. 289-296.	
	B30	Catherine S. MURPHY et al., "Structure-Function Relationships of Hydroxylated Metabolites of Tamoxifen that Control the Proliferation of Estrogen-Responsive T47D Breast Cancer Cells In Vitro", Molecular Pharmacology, Vol. 38, No. 5, (1990), pp. 737-743.	
	B31	Mona NEMANI et al., "Activation of the human homologue of the Drosophila sina gene in apoptosis and tumor suppression", Proc. Natl. Acad. Sci. USA, Vol. 93, pp. 9039-9042, August 1996.	
	B32	Y. NOMURA et al., "Effects of antiestrogens and medroxyprogesterone acetate on the clonogenic growth of tamoxifen-sensitive and resistant human breast cancer cells", Japanese Journal of Cancer Chemotherapy, 12(4), pp. 844-850 (1985)	
	B33	Naushin H. WASEEM et al., "Monoclonal Antibody Analysis of the Proliferating Cell Nuclear Antigen (PCNA) Structural conservation and the detection of a nucleolar form, Journal of Cell Science, 96, 121-129 (1990).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.